Daily treatment with the sleep hormone melatonin prevented the narrowing of the lung’s blood vessels, the underlying cause of pulmonary arterial hypertension (PAH), in a rat study. Melatonin also prevented signs of heart injury and neutralized reactive oxygen species (ROS), chemically reactive molecules that can damage cells. “These data…
News
The Pulmonary Hypertension Association (PHA) has launched its “Living Under Pressure” campaign to kick off Pulmonary Hypertension Awareness Month this November, highlighting the daily physical and emotional challenges of living with the rare disease. The organization joins other advocates worldwide to raise awareness…
A score based on three routine blood tests may help identify people with pulmonary hypertension (PH) who are at higher risk of dying or being hospitalized for heart failure within about a year, a study in Turkey suggests. The platelet–albumin–bilirubin index, or PALBI, helped distinguish people…
The American College of Chest Physicians (CHEST) is launching a first-of-its-kind education and certification program for nurse practitioners (NPs) and physician assistants/associates (PAs) who are interested in treating people with lung diseases such as pulmonary hypertension. CHEST announced the program after completing a comprehensive discovery initiative examining…
Liquidia and United Therapeutics have entered into a global settlement that ends a yearslong legal dispute over Yutrepia, Liquidia’s dry powder inhalation formulation of the medication treprostinil. Under the settlement, Liquidia will maintain access to Yutrepia for people with pulmonary arterial hypertension (PAH), but pull the…
Over the past three decades, rates of pulmonary arterial hypertension (PAH) have increased in wealthy parts of the world, including the U.S. and Europe — but though the rare disease has become more common in richer nations, the rates of death due to PAH have nonetheless decreased over time…
A marker on a CT scan could help identify pulmonary fibrosis patients who need further evaluation for pulmonary hypertension (PH), a study found. Among people with progressive pulmonary fibrosis, PH was linked to a larger pulmonary artery-to-aorta (PA/Ao) ratio on CT scans, an indirect sign that has been reported…
People newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) who have lower exercise capacity and poorer breathing efficiency during exercise tend to also report more severe anxiety and depressive symptoms, according to a new study in China. “The present findings … support greater attention to psychological symptoms during the…
Artificial intelligence (AI) tools using machine learning may help doctors predict how a pulmonary arterial hypertension (PAH) patient’s ability to walk might change over the next year, a study from Germany found. The researchers said more study is needed before the machine learning model, which uses clinical data available…
Note: This story was updated Sept. 30, 2026, to clarify that the Chiesi Group is no longer collaborating with Gossamer Bio in the development, regulatory activities, or commercialization of seralutinib. Gossamer Bio has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of seralutinib, an…
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Winrevair (sotatercept-csrk), an approved injection therapy for adults with pulmonary arterial hypertension (PAH) marketed by Merck. The most notable change in this update is the addition of a contraindication (a…
A national database study found substantial variation in how clinicians manage people hospitalized with pulmonary arterial hypertension (PAH) who presented with shock, a life-threatening lack of blood flow to the body’s organs. Researchers identified 25 different initial treatment strategies involving vasoactive medications, drugs that adjust blood pressure and heart…
